Compare Becton Dickinson and Co (BDX) vs Vital Farms Inc (VITL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Becton Dickinson and Co vs Vital Farms Inc — how do they compare? Becton Dickinson and Co trades at $181.29 (market cap $48.93B), while Vital Farms Inc trades at $11.57 (market cap $483.84M). The key difference: Becton Dickinson and Co is far larger — about 101.1× Vital Farms Inc's market cap, and Becton Dickinson and Co pays a 2.34% dividend while Vital Farms Inc pays none. Which is the better fit depends on your goals.
| BDX | VITL | |
|---|---|---|
Market Cap | $48.93B | $483.84M |
Sector | Health | Consumer Staples |
52-Week High | $185.39 | $52.41 |
52-Week Low | $138.62 | $8.28 |
Enterprise Value | $65.03B | $570.85M |
Dividend Yield | 2.34% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BDX (Becton, Dickinson and Company) trades at $176.86, down 0.12% on the day, with a bullish technical outlook supported by moving averages and strong earnings beats in recent quarters. The company reported Q3 2026 revenue of $5.0 billion, up 4.4% FX-neutral, and raised full-year guidance, though margins faced pressure. Analyst sentiment is mixed with a consensus price target of $183.00, while institutional ownership remains stable amid positive news on GLP-1 therapy expansions and dividend declarations.
The stock offers steady growth potential with a 2.7% dividend yield and consistent earnings outperformance, but risks include margin compression, regulatory recalls, and high valuation multiples. Near-term resistance at $180 and support at $173 will test bullish momentum, with the current price near the consensus target suggesting limited upside without further catalysts.
Vital Farms (VITL) trades at $12.24, down 2.16% amid bearish technical signals and challenging Q2 2026 results with a net loss of $0.47 per share. Revenue declined 10.1% year-over-year to $166 million due to industry oversupply and competitive pressures. The company secured $125 million in term loan financing in August 2026 to support operations. Analyst consensus remains positive with a $13.00 price target and 56% buy ratings, though profitability metrics show significant compression with net income margin at 0.02%.
The stock faces near-term headwinds from operational challenges but maintains analyst support. Investment opportunity exists if the company can navigate industry oversupply and restore profitability. Key risks include persistent margin pressure, competitive pricing gaps, and execution of the new financing strategy. The current valuation at 11.77 P/E appears reasonable if earnings recovery materializes.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Becton Dickinson and Co
Becton, Dickinson is the world's largest manufacturer and distributor of medical surgical products, such as needles, syringes, and sharps-disposal units. The company also manufactures diagnostic instruments and reagents, as well as flow cytometry and cell-imaging systems. BD Interventional (largely the former Bard business) accounts for 23% of revenue. International revenue accounts for 44% of the company's business.
Read more on BDX →About Vital Farms Inc
Vital Farms is a leading provider of ethically produced, pasture-raised eggs and butter in the United States. Operating as a Public Benefit Corporation, it manages a network of over 650 family farms to deliver high-welfare food products. It leverages a scalable 'asset-light' partnership model that prioritizes transparency and animal welfare to meet the growing consumer demand for clean-label and sustainable food sources.
Read more on VITL →
